CYP

8.89%

24.5¢

CYNATA THERAPEUTICS LIMITED

Market Cap $43.11M Add to my watchlist

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Latest Threads

Tag

Subject

CYP

Ann: Investor Presentation

12/05/24

5.9K

12/05/24

Last post gavint66

5.9K

CYP

Ann: Quarterly Activity Report & Appendix 4C

07/05/24

6.6K

07/05/24

Last post flotsam222

6.6K

CYP

Stem Cell News

7 8 9

28/04/24

514

118K

28/04/24

Last post Valueformoney

514

118K

CYP

Ann: Recruitment Completed in Phase 3 OA Clinical Trial

23/04/24

2.6K

23/04/24

Last post Pledge

2.6K

CYP

Going forward...

34 35 36

18/04/24

2.1K

679K

18/04/24

Last post gavint66

2.1K

679K

CYP

Ann: Notification regarding unquoted securities - CYP

17/04/24

1.0K

17/04/24

Last post JB1975

1.0K

CYP

Ann: DFU Clinical Trial Enrolment Complete

17/04/24

5.6K

17/04/24

Last post Pledge

5.6K

CYP Biotech

Timelines

15/04/24

1.1K

15/04/24

Last post viewph

1.1K

See All Discussions

Timeline

Investor Presentation
07 May 11:35	Share

Quarterly Activity Report & Appendix 4C
30 Apr 08:54	Share

Notification regarding unquoted securities - CYP
17 Apr 13:36	Share

DFU Clinical Trial Enrolment Complete
08 Apr 08:58	Share

EU Approval for Phase 2 CYP-001 Trial in GvHD
20 Mar 08:55	Share

Cynata Presenting at Advanced Therapies Congress
18 Mar 08:52	Share

First Patient Treated in Phase 2 GvHD Trial
05 Mar 08:54	Share

Cynata Appoints New Chief Business Officer
29 Feb 09:19	Share

Encouraging Initial Data from CYP-006TK DFU Trial
26 Feb 09:01	Share

Appendix 4D & Half-Year Financial Statements
23 Feb 15:22	Share

Quarterly Activity Report & Appendix 4C
30 Jan 08:56	Share

Notification regarding unquoted securities - CYP
16 Jan 16:29	Share

Initial Results in First 16 DFU Patients Expected in Q1 2024
28 Dec 08:52	Share

Recruitment Completed in Phase 3 OA Clinical Trial
13 Dec 09:46	Share

Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey
07 Dec 09:39	Share

Appendix 3Y - Dr Kilian Kelly
23 Nov 09:13	Share

Appendix 3Ys x 5
20 Nov 16:41	Share

Notification regarding unquoted securities - CYP
20 Nov 16:31	Share

Notification of cessation of securities - CYP
14 Nov 16:29	Share

Cynata Receives $2.315m R&D Tax Incentive Refund
14 Nov 08:55	Share

Final Director's Interest Notice
13 Nov 14:45	Share

Results of AGM
13 Nov 12:40	Share

AGM Presentations
13 Nov 08:32	Share

Phase 3 SCUlpTOR Osteoarthritis Clinical Trial Progress
06 Nov 09:14	Share

First USA site initiated in aGvHD trial
02 Nov 09:30	Share

Quarterly Activity Report & Appendix 4C
26 Oct 14:18	Share

Annual Report to Shareholders
12 Oct 14:43	Share

Letter to Shareholders, Notice of AGM & Proxy Form
12 Oct 14:41	Share

Dr David Atkins not to stand for re-election at AGM
09 Oct 08:57	Share

Investor Webinar Presentation
18 Sep 16:33	Share

View More

(20min delay)
Last 24.5¢		Change 0.020(8.89%)		Mkt cap ! $43.11M

Open	High	Low	Value	Volume
23.0¢	25.0¢	22.5¢	$64.55K	275.3K

Buyers (Bids)

No.	Vol.	Price($)
2	8406	24.0¢

Sellers (Offers)

Price($)	Vol.	No.
24.5¢	26070	2

View Market Depth

No.	Vol.	Price($)
2	8406	0.240
2	38276	0.235
1	21000	0.230
1	490130	0.225
4	114192	0.220

Price($)	Vol.	No.
0.245	5380	1
0.250	45006	3
0.275	21895	1
0.280	5000	1
0.290	29799	1

Last trade - 15.32pm 13/05/2024 (20 minute delay)


Last 24.5¢		Change 0.020 ( 6.52 %)
Open	High	Low	Volume
23.0¢	24.5¢	23.0¢	19904
Last updated 14.37pm 13/05/2024 ?

CYP (ASX) Chart

CYNATA THERAPEUTICS LIMITED

Latest Threads

Hillcrest Returns to the UK and Provides Additional Shareholder Updates

Timeline

Featured News

Latest Videos

Cynata Therapeutics (ASX:CYP) receives approval for acute graft-versus-host disease clinical trial

30 Jan 2023 14:49 (AEDT)

Latest Articles

Cynata wins EU ethics approval for phase 2 Trial of CYP-001

Cynata Therapeutics has been given EU regulatory and ethics approval for phase 2 Trial of its latest development 'CYP-001'

Cynata Therapeutics advances Phase 2 trial for high-risk aGvHD treatment

The market has responded favourably to Cynata Therapeutics' announcement regarding its Phase 2 clinical trial on graft versus host disease.

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase II clinical trial using its drug candidate, CYP-001.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News